 Immunoglobulin Light Chains
"Immunoglobulin Light Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
| Descriptor ID |
D007147
|
| MeSH Number(s) |
D12.776.124.486.485.705.750 D12.776.124.790.651.705.750 D12.776.377.715.548.705.750
|
| Concept/Terms |
Immunoglobulin Light Chains- Immunoglobulin Light Chains
- Chains, Immunoglobulin Light
- Light Chains, Immunoglobulin
- Immunoglobulin Light-Chain
- Light-Chain, Immunoglobulin
- Light-Chain Immunoglobulins
- Light Chain Immunoglobulins
- Immunoglobulin Light Chain
- Light Chain, Immunoglobulin
- Immunoglobulins, Light-Chain
- Immunoglobulins, Light Chain
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Light Chains".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Light Chains".
This graph shows the total number of publications written about "Immunoglobulin Light Chains" by people in this website by year, and whether "Immunoglobulin Light Chains" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2010 | 0 | 3 | 3 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoglobulin Light Chains" by people in Profiles.
-
Ohlstrom D, Walker ZJ, Pandey A, Davis LN, Engel KL, Pan Z, Forsberg PA, Mark TM, Gillen AE, Sherbenou DW. Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression. Cancer Res Commun. 2025 01 01; 5(1):106-118.
-
Rhodes ER, Faris JG, Petersen BM, Sprenger KG. Common framework mutations impact antibody interfacial dynamics and flexibility. Front Immunol. 2023; 14:1120582.
-
Banach M, Harley ITW, Getahun A, Cambier JC. Comparative analysis of the repertoire of insulin-reactive B cells in type 1 diabetes-prone and resistant mice. Front Immunol. 2022; 13:961209.
-
Banach BB, Cerutti G, Fahad AS, Shen CH, Oliveira De Souza M, Katsamba PS, Tsybovsky Y, Wang P, Nair MS, Huang Y, Francino-Urd?niz IM, Steiner PJ, Guti?rrez-Gonz?lez M, Liu L, L?pez Acevedo SN, Nazzari AF, Wolfe JR, Luo Y, Olia AS, Teng IT, Yu J, Zhou T, Reddem ER, Bimela J, Pan X, Madan B, Laflin AD, Nimrania R, Yuen KY, Whitehead TA, Ho DD, Kwong PD, Shapiro L, DeKosky BJ. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Cell Rep. 2021 10 05; 37(1):109771.
-
Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodr?guez-Lobato LG, Oliver-Cald?s A, Salgado MC, Bras?-Maristany F, Yag?e J, Cibeira MT, Prat A, Rosi?ol L, Blad? J, Fern?ndez de Larrea C. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Ann Hematol. 2021 Dec; 100(12):2997-3005.
-
Chyra Z, Sevcikova T, Vojta P, Puterova J, Brozova L, Growkova K, Filipova J, Zatopkova M, Grosicki S, Barchnicka A, Jedrzejczak WW, Waszczuk-Gajda A, Jungova A, Mikulasova A, Hajduch M, Mokrejs M, Pour L, Stork M, Harvanova L, Mistrik M, Mikala G, Robak P, Czyz A, Debski J, Usnarska-Zubkiewicz L, Jurczyszyn A, Stejskal L, Morgan G, Kryukov F, Budinska E, Simicek M, Jelinek T, Hrdinka M, Hajek R. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica. 2021 02 01; 106(2):601-604.
-
Rana R, Cockwell P, Drayson M, Cook M, Pratt G, Cairns DA, Pawlyn C, Jackson G, Davies F, Morgan G, Pinney JH. Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Adv. 2020 11 24; 4(22):5836-5845.
-
Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 10 16; 10(10):102.
-
Morgan GJ, Wall JS. The Process of Amyloid Formation due to Monoclonal Immunoglobulins. Hematol Oncol Clin North Am. 2020 12; 34(6):1041-1054.
-
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 07 02; 136(1):71-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|